Abstract:BACKGROUND: Sickle cell disease (SCD) and its complications contribute to high rates of morbidity and early mortality and high cost in the United States and African heritage community.OBJECTIVE: To evaluate the cost-effectiveness of gene therapy for SCD and its value-based prices (VBPs).DESIGN: Comparative modeling analysis across 2 independently developed simulation models (University of Washington Model for Economic Analysis of Sickle Cell Cure [UW-MEASURE] and Fred Hutchinson Institute Sickle Cell Disease Outcomes Research and Economics Model [FH-HISCORE]) using the same databases.DATA SOURCES: Centers for Medicare & Medicaid Services claims data, 2008 to 2016; published literature.TARGET POPULATION: Persons eligible for gene therapy.TIME HORIZON: Lifetime.PERSPECTIVE: U.S. health care sector and societal.INTERVENTION: Gene therapy versus common care.OUTCOME MEASURES: Incremental cost-effectiveness ratios (ICERs), equity-informed VBPs, and price acceptability curves.RESULTS OF BASE-CASE ANALYSIS: At an assumed $2 million price for gene therapy, UW-MEASURE and FH-HISCORE estimated ICERs of $193 000 per QALY and $427 000 per QALY, respectively, under the health care sector perspective. Corresponding estimates from the societal perspective were $126 000 per QALY and $281 000 per QALY. The difference in results between models stemmed primarily from considering a slightly different target population and incorporating the quality-of-life (QOL) effects of splenic sequestration, priapism, and acute chest syndrome in the UW model. From a societal perspective, acceptable (>90% confidence) VBPs ranged from $1 million to $2.5 million depending on the use of alternative effective metrics or equity-informed threshold values.RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to the costs of myeloablative conditioning before gene therapy, effect on caregiver QOL, and effect of gene therapy on long-term survival.LIMITATION: The short-term effects of gene therapy on vaso-occlusive events were extrapolated from 1 study.CONCLUSION: Gene therapy for SCD below a $2 million price tag is likely to be cost-effective when applying a societal perspective at an equity-informed threshold for cost-effectiveness analysis.PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.

How I Treat Sickle Cell Disease with Gene Therapy

Treating Sickle Cell Disease: Gene Therapy Approaches

Current state of gene therapy in sickle cell disease

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease

Gene Therapies for Sickle Cell Disease

Role of gene therapy in sickle cell disease

Gene therapy in sickle cell disease: Attitudes and informational needs of patients and caregivers

Blood Spotlight Review on Gene Therapy for Sickle Cell Disease

Is Allogeneic Transplantation for Sickle Cell Disease Still Relevant in the Era of Gene Therapy?

Fostering a healthier generation of children with sickle cell disease through advancements in care

Curative Therapies for Sickle Cell Disease

Advancing life: innovative approaches to enhance survival in sickle cell anemia patients

Novel gene therapies for sickle cell disease, Duchenne muscular dystrophy, and hemophilia A

Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease

Newer Modalities and Updates in the Management of Sickle Cell Disease: A Systematic Review

Hematopoietic stem cell collection for sickle cell disease gene therapy

Successes and challenges in clinical gene therapy

Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease in the United States

Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review